Why cancer drug programs need human mass balance studies
Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…
Certara2024 年 9 月 23 日
A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule‑1 Biomarker
Discover how PK‑TD modelling shows palonosetron reduces platinum exposure and KIM‑1 elevations versus other antiemetics…
Certara2024 年 9 月 20 日
Intravenous Versus Intraosseous Use of Tranexamic Acid in Patients With Traumatic Brain Injury
See how IV and intraosseous TXA show similar total exposure in prehospital TBI care, analysed…
Certara2024 年 9 月 2 日
Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome
Learn how triple‑drug combinations increase clobazam metabolite exposure and improve seizure control, modelled using Phoenix…
Certara2024 年 8 月 30 日
In Vivo Activity of Intestinal P-Glycoprotein and Hepatic Organic Anion Transporters Polypeptide in Pregnancy and Postpartum
Find out how rosuvastatin exposure increases during pregnancy due to reduced OATP activity, while P‑gp…
Certara2024 年 8 月 27 日
Resmetirom: A pioneering NASH clinical program
Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…
Certara2024 年 8 月 23 日
Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…
Certara2024 年 8 月 19 日
